Invasive mould infections: a multi-disciplinary update.

Details

Ressource 1Download: serval:BIB_897D2B8D9C1E.P001 (201.28 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_897D2B8D9C1E
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Invasive mould infections: a multi-disciplinary update.
Journal
Medical Mycology
Author(s)
Maschmeyer G., Calandra T., Singh N., Wiley J., Perfect J.
ISSN
1369-3786
ISSN-L
1369-3786
Publication state
Published
Issued date
2009
Peer-reviewed
Oui
Volume
47
Number
6
Pages
571-583
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review Publication Status: ppublish
Abstract
Systemic fungal infections remain a significant cause of mortality in neutropenic and immunocompromised patients, despite advances in their diagnosis and treatment. The incidence of such infections is rising due to the use of intensive chemotherapy regimens in patients with solid tumours or haematological cancers, the increasing numbers of allogeneic haematopoietic stem cell and solid organ transplants, and the use of potent immunosuppressive therapy in patients with autoimmune disorders. In addition, the epidemiology of systemic fungal infections is changing, with atypical species such as Aspergillus terreus and zygomycetes becoming more common. Treatment has traditionally focused on empirical therapy, but targeted pre-emptive therapy in high-risk patients and prophylactic antifungal treatment are increasingly being adopted. New treatments, including lipid formulations of amphotericin B, second-generation broad-spectrum azoles, and echinocandins, offer effective antifungal activity with improved tolerability compared with older agents; the potential impact of these treatments is reflected in their inclusion in current treatment and prophylaxis guidelines. New treatment strategies, such as aerosolized lipid formulations of amphotericin B, may also reduce the burden of mortality associated with systemic fungal infections. The challenge is to identify ways of coupling potentially effective treatments with early and reliable identification of patients at highest risk of infection.
Keywords
Antifungal Agents/therapeutic use, Chemoprevention, Humans, Mycological Typing Techniques/methods, Mycoses/diagnosis, Mycoses/drug therapy, Organ Transplantation
Pubmed
Web of science
Open Access
Yes
Create date
07/10/2009 17:16
Last modification date
25/09/2019 7:09
Usage data